Intranasal drugs are an important part of migraine treatment. Migraine headache attacks are prevented by using these medicines. It assists in reducing headache pain and other symptoms like sensitivity to sound or light. Timely treatment enables a patient to get back to their normal routine shortly and may lessen your requirement for different pain medications. Migraine occurrences are not be prevented by this medication. New product launches by key manufacturers, rising R&D activities, and quick drug approvals by regulatory bodies such as the U.S. Food and Drug Administration for chronic and acute migraines have anticipated providing profitable opportunities in the coming years.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the intranasal migraine drugs market.
Top Impacting Factors
- Increase in cases of acute migraine and chronic sinusitis, rise in demand for advanced treatments, and surge in healthcare expenditure are factors that drive the growth of the intranasal migraine drugs market.
- In addition, collaborations, mergers & acquisitions between key players to facilitate drug development; rise in R&D activities to improve quality of drugs; launch of the novel developed drug in market; and technological advancements are some factors, which boost the market growth for intranasal migraine drugs.
- However, less awareness for the alternative treatment for lung diseases, side effects linked with the drugs such as quick heartbeat, shortness of breath, and more may hinder the intranasal migraine drugs market growth. intranasal migraine drugs market
- Contrarily, favorable reimbursement policies and support from the government for regulatory approval present new pathways in the industry.
Intranasal migraine drugs Market Trends
New product launches to flourish the market
In January 2021, Impel Neuro Pharma received U.S. Food and Drug Administration (FDA) approval for the new drug application for INP104, for the acute treatment of migraine headaches.
In March 2021, Cipla received U.S FDA approval to treat migraine attacks for a nasal spray.
In June 2020, Tonix Pharmaceuticals acquired pain and non-addictive migraine treatment programs of Trigemina Inc. and will also acquire the license of TNX-1900 intranasal oxytocin. It has the potential to treat craniofacial pain and migraine.
In January 2019, Dr. Reddy's Laboratories received the US Food and Drug Administration (FDA) approval for a sumatriptan nasal splash to provide the intense therapy for headache.
Key Benefits of the Report
- This study presents the analytical depiction of the intranasal migraine drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the intranasal migraine drugs market share.
- The current market is quantitatively analyzed to highlight the intranasal migraine drugs market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the intranasal migraine drugs market.
- The report provides a detailed intranasal migraine drugs market analysis based on competitive intensity and how the competition will take shape in coming years
Questions answered in the intranasal migraine drugs Report
- Which are the leading players active in the intranasal migraine drugs market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the intranasal migraine drugs market?
- What future projections would help in taking further strategic steps?
- What is "Intranasal migraine drugs"?
- What is "Intranasal migraine drugs” Market prediction in the future?
- Who are the leading global players in the "Intranasal migraine drugs" Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Intranasal migraine drugs” Market report?
Intranasal migraine drugs Market Report Highlights
| Aspects | Details |
 By Therapeutic Class |
|
 By Indication |
|
 By Range |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Novartis AG, Aegis Therapeutics LLC, Roche, Baxter International Inc., Merck, Lockhart ltd, Sanofi, Dr. Reddy’s Laboratories, Neuro Pharma, Pfizer Inc. |
Loading Table Of Content...
